Skip to content
RKWD
ROCKWOOD RESEARCH · A CORPORATE FILINGS WEBSITE|STRAIGHT FROM THE SOURCE · SEC EDGAR|SPONSOREDYour message on this tape — bid on the Rockwood Ad Exchange · Rockwood Ad Exchange|
Rockwood Research
…

STRO

SUTRO BIOPHARMA, INC.

Biological Products, (No Diagnostic Substances) · SIC 2836CIK 1382101Held by 1 tracked managerEDGAR filings ↗10-K/10-Q ↗

SHARE:XLINKEDINEMAIL
Revenue FY2025
$102.0M
Net Income FY2025
$(191.0M)
EPS (Basic, as reported)
$-22.49
Net Margin FY2025
-186.5%
ROE FY2025
144.3%
Total Equity
$(132.0M)
Shares Out
17M
Business description

SUTRO BIOPHARMA, INC. — Biological Products, (No Diagnostic Substances). Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2016–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.

Annual (fiscal years, as reported)USD millions
i
default rows · click any row to chart itRevenue: 60 → 102 +6.1% CAGR
Fiscal yearFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024⚑FY2025
Revenue6052384343626815462102
Research & development(44)(55)(54)(66)(77)(104)(137)(180)(252)(166)
General & administrative(15)(16)(21)(33)(37)(56)(60)(63)(48)(41)
Total operating expenses(58)(71)(76)(98)(114)(160)(197)(243)(300)(261)
Operating income1(19)(37)(55)(71)(99)(129)(89)(238)(158)
Interest expense0(1)(2)(1)(2)(3)(2)(1)——
Other income (expense), net002———————
Pre-tax income————(32)(106)(117)(89)(225)(191)
Income tax expense—00000(2)(18)(2)0
Net income2(20)(35)(56)(32)(106)(119)(107)(227)(191)
EPS — basic————($0.99)($2.29)($2.35)($1.78)($2.96)($22.49)
EPS — diluted————($0.99)($2.29)($2.35)($1.78)($2.96)($22.49)
Shares outstanding — basic (M)————33465160778
Shares outstanding — diluted (M)————33465160778
  • ⚑ Weighted-average shares changed ÷10.00 between FY2024 and FY2025 — likely a reverse split. Per-share figures on either side are as reported and not adjusted.

Source: SEC EDGAR XBRL company facts — figures as reported in each period's original filing (structured data begins ~2008). EPS and other per-share figures are as reported and are not adjusted for later stock splits; a ⚑ marks a period where the reported share count changed by a large factor. Dollar figures in millions unless per-share. Line items a company never reports are omitted. Where a filer switched XBRL concepts, the successor concept is used and definitions can differ slightly (e.g. cash may include restricted cash; banks' revenue is net of interest expense; cost of revenue may exclude D&A; net income may be the amount available to common stockholders; debt issued/repaid may be net of issuance costs or include finance-lease obligations — each only where the original concept stopped being reported). Click a period header to open that period's source filing on EDGAR.